Available to investors in the GCC through Swissquote MEA, Swissquote’s Pharma Opportunity Certificate allows its clients to invest in a comprehensive and diversified portfolio
By Staff Writer, Arab News
Swissquote Bank Ltd., a global provider of online financial and trading services, has announced a new trading certificate, which enables investors to actively support companies in their fight against COVID-19.
Available to investors in the GCC through Swissquote MEA, Swissquote’s Pharma Opportunity Certificate allows its clients to invest in a comprehensive and diversified portfolio of the world’s leading pharmaceutical and biotech companies that are seeking solutions to put an end to the pandemic.
Dino Ibric, vice director at Swissquote MEA, said: “The year 2020 will undoubtedly go down in history as the year of COVID-19.
“While most of us feel powerless in the face of all these events, our clients now have the opportunity to support the fight against the coronavirus by investing in companies that are researching the solutions for it.”
There has been an unprecedented eruption of global pharmaceutical research and development related to COVID-19. More than 330 clinical studies and 80 vaccine candidates are currently under review, while big pharma and biotech companies across the world are working to find a drug to manage or defeat COVID-19. With the Pharma Opportunity Certificate, Swissquote’s customers can now invest in the performance of companies that are actively working on medicines to combat the coronavirus by developing vaccines or treatments.
Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.